WallStSmart

Adapthealth Corp (AHCO)vsDexCom Inc (DXCM)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

DexCom Inc generates 47% more annual revenue ($4.82B vs $3.29B). DXCM leads profitability with a 19.3% profit margin vs -2.4%. DXCM earns a higher WallStSmart Score of 72/100 (B).

AHCO

Hold

45

out of 100

Grade: D+

Growth: 5.3Profit: 3.0Value: 6.7Quality: 3.5
Piotroski: 4/9Altman Z: 0.95

DXCM

Strong Buy

72

out of 100

Grade: B

Growth: 8.7Profit: 8.5Value: 6.7Quality: 7.0
Piotroski: 5/9Altman Z: 2.67
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

AHCOUndervalued (+66.7%)

Margin of Safety

+66.7%

Fair Value

$31.68

Current Price

$10.79

$20.89 discount

UndervaluedFair: $31.68Overvalued
DXCMUndervalued (+89.6%)

Margin of Safety

+89.6%

Fair Value

$656.95

Current Price

$75.14

$581.81 discount

UndervaluedFair: $656.95Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

AHCO1 strengths · Avg: 10.0/10
Price/BookValuation
1.0x10/10

Reasonable price relative to book value

DXCM4 strengths · Avg: 9.0/10
Return on EquityProfitability
31.5%10/10

Every $100 of equity generates 31 in profit

EPS GrowthGrowth
92.2%10/10

Earnings expanding 92.2% YoY

Operating MarginProfitability
21.4%8/10

Strong operational efficiency at 21.4%

Revenue GrowthGrowth
15.0%8/10

15.0% revenue growth

Areas to Watch

AHCO4 concerns · Avg: 2.8/10
Market CapQuality
$1.49B3/10

Smaller company, higher risk/reward

Operating MarginProfitability
0.7%3/10

Operating margin of 0.7%

Debt/EquityHealth
1.333/10

Elevated debt levels

Return on EquityProfitability
-5.3%2/10

ROE of -5.3% — below average capital efficiency

DXCM2 concerns · Avg: 4.0/10
P/E RatioValuation
32.9x4/10

Premium valuation, high expectations priced in

Price/BookValuation
9.8x4/10

Trading at 9.8x book value

Comparative Analysis Report

WallStSmart Research

Bull Case : AHCO

The strongest argument for AHCO centers on Price/Book.

Bull Case : DXCM

The strongest argument for DXCM centers on Return on Equity, EPS Growth, Operating Margin. Profitability is solid with margins at 19.3% and operating margin at 21.4%. Revenue growth of 15.0% demonstrates continued momentum.

Bear Case : AHCO

The primary concerns for AHCO are Market Cap, Operating Margin, Debt/Equity.

Bear Case : DXCM

The primary concerns for DXCM are P/E Ratio, Price/Book.

Key Dynamics to Monitor

AHCO profiles as a turnaround stock while DXCM is a mature play — different risk/reward profiles.

DXCM carries more volatility with a beta of 1.45 — expect wider price swings.

DXCM is growing revenue faster at 15.0% — sustainability is the question.

DXCM generates stronger free cash flow (449M), providing more financial flexibility.

Bottom Line

DXCM scores higher overall (72/100 vs 45/100), backed by strong 19.3% margins and 15.0% revenue growth. AHCO offers better value entry with a 66.7% margin of safety. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Adapthealth Corp

HEALTHCARE · MEDICAL DEVICES · USA

AdaptHealth Corp. The company is headquartered in Plymouth Meeting, Pennsylvania.

Visit Website →

DexCom Inc

HEALTHCARE · MEDICAL DEVICES · USA

DexCom, Inc. is a company that develops, manufactures, and distributes continuous glucose monitoring (CGM) systems for diabetes management. It operates internationally with headquarters in San Diego, California, and has a manufacturing facility in Mesa, Arizona.

Want to dig deeper into these stocks?